Literature DB >> 18184943

Brain proton magnetic resonance spectroscopy and neuromuscular pathology in a patient with GM1 gangliosidosis.

Nicola Brunetti-Pierri1, Meenakshi B Bhattacharjee, Zhiyue J Wang, David A Wenger, Lorraine Potocki, Jill Hunter, Fernando Scaglia.   

Abstract

The authors report the clinical, neuroradiologic, and neuromuscular pathological findings in a patient with GM1 gangliosidosis. The proton magnetic resonance spectroscopy, previously reported in a single patient with GM1 gangliosidosis, detected a mild reduction of N-acetylaspartate, consistent with relative paucity of axons and neurons and increased levels of myoinositol suggestive of gliotic white matter changes along with the accumulation of an additional compound that could represent either guanidinoacetate or Gal beta 1-6Gal beta 1-4)GlcNAc, an oligosaccharide previously isolated from the urine of GM1 gangliosidosis patients. Although these findings will have to be further confirmed in more patients with GM1 gangliosidosis, they suggest that proton magnetic resonance spectroscopy may provide useful end points to assess the efficacy of novel treatments that could soon become clinically available. Histologically, no significant alterations were found in axons, but there was evidence of redundant and inappropriately folded myelin, which is a feature attributed to disturbed axon-glial interactions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18184943     DOI: 10.1177/0883073807307088

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  6 in total

1.  Novel Biomarkers of Human GM1 Gangliosidosis Reflect the Clinical Efficacy of Gene Therapy in a Feline Model.

Authors:  Heather L Gray-Edwards; Debra S Regier; Jamie L Shirley; Ashley N Randle; Nouha Salibi; Sarah E Thomas; Yvonne L Latour; Jean Johnston; Gretchen Golas; Annie S Maguire; Amanda R Taylor; Donald C Sorjonen; Victoria J McCurdy; Peter W Christopherson; Allison M Bradbury; Ronald J Beyers; Aime K Johnson; Brandon L Brunson; Nancy R Cox; Henry J Baker; Thomas S Denney; Miguel Sena-Esteves; Cynthia J Tifft; Douglas R Martin
Journal:  Mol Ther       Date:  2017-02-22       Impact factor: 11.454

2.  Rare Diseases in Glycosphingolipid Metabolism.

Authors:  Hongwen Zhou; Zhoulu Wu; Yiwen Wang; Qinyi Wu; Moran Hu; Shuai Ma; Min Zhou; Yan Sun; Baowen Yu; Jingya Ye; Wanzi Jiang; Zhenzhen Fu; Yingyun Gong
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 3.  Guanidinoacetic Acid as a Nutritional Adjuvant to Multiple Sclerosis Therapy.

Authors:  Sergej M Ostojic
Journal:  Front Hum Neurosci       Date:  2022-05-12       Impact factor: 3.473

Review 4.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

5.  Myelin abnormalities in the optic and sciatic nerves in mice with GM1-gangliosidosis.

Authors:  Karie A Heinecke; Adrienne Luoma; Alessandra d'Azzo; Daniel A Kirschner; Thomas N Seyfried
Journal:  ASN Neuro       Date:  2015-02-18       Impact factor: 4.146

6.  7T MRI Predicts Amelioration of Neurodegeneration in the Brain after AAV Gene Therapy.

Authors:  Heather L Gray-Edwards; Anne S Maguire; Nouha Salibi; Lauren E Ellis; Taylor L Voss; Elise B Diffie; Jey Koehler; Ashley N Randle; Amanda R Taylor; Brandon L Brunson; Thomas S Denney; Ronald J Beyers; Atoska S Gentry; Amanda L Gross; Ana R Batista; Miguel Sena-Esteves; Douglas R Martin
Journal:  Mol Ther Methods Clin Dev       Date:  2019-12-24       Impact factor: 6.698

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.